Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Significance: As health officials face another wave of COVID-19, they require estimates of the proportion of infected cases that develop symptoms, and the extent to which symptomatic and asymptomatic cases contribute to community transmission. Recent asymptomatic testing guidelines are ambiguous. Using an epidemiological model that includes testing capacity, we show that many infections are nonsymptomatic but contribute substantially to community transmission in the aggregate. Their individual transmissibility remains uncertain. If they transmit as well as symptomatic infections, the epidemic may spread at faster rates than current models often assume. If they do not, then each symptomatic case generates, on average, a higher number of secondary infections than typically assumed. Regardless, controlling transmission requires community-wide interventions informed by extensive, well-documented asymptomatic testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254 · cited 1×
“The alternative 254 approach of fitting the models to death data is not necessarily 255 exempt from biases in parameter estimates, due to changes 256 in hospital capacity over time(31, 32), co-morbidities in host 257 populations(33, 34), and the long delay between the onset of 258 infection and death(35).”
MethodInfectious Diseases of Humans: Dynamics and Control
Anderson, R. M., & May, R. M. (1991) · doi:10.1093/oso/9780198545996.001.0001 · Cited by 6,179
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633 · cited 3×
“While some early models of the COVID-19 63 outbreak in Wuhan attempted to take into account changes 64 in testing capacity(21) or differences in reporting rate during 65 periods of the epidemic(9), the limited information on these 66 trends in Wuhan meant that they had to be estimated on 67 a coarse temporal scale (2-…”
BackgroundGrifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662 · cited 1×
“The immune response to the SARS-CoV virus consists of several components including antibody (60) and T-cell mediated (61) responses, and heterogeneity in particular pathways of the immune response can influence the severity of infections (62, 63).”
BackgroundSuperspreading and the effect of individual variation on disease emergence
Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E., & Getz, W. M. (2005) · Nature · doi:10.1038/nature04153 · Cited by 2,514 · cited 1×
“In classic super-spreading dy- 290 namics, most primary cases do not result in many secondary 291 cases, while a subset of primary cases result in a large num- 292 ber of secondary cases(8, 49, 50).”
BackgroundInborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229 · cited 1×
“The immune response to the SARS-CoV virus consists of several components including antibody (60) and T-cell mediated (61) responses, and heterogeneity in particular pathways of the immune response can influence the severity of infections (62, 63).”
BackgroundPan, A., Liu, L., Wang, C., Guo, H., Hao, X., Wang, Q., Huang, J., He, N., Yu, H., Lin, X., et al. (2020) · JAMA · doi:10.1001/jama.2020.6130 · Cited by 1,931
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660 · cited 1×
“The alternative 254 approach of fitting the models to death data is not necessarily 255 exempt from biases in parameter estimates, due to changes 256 in hospital capacity over time(31, 32), co-morbidities in host 257 populations(33, 34), and the long delay between the onset of 258 infection and death(35).”
MethodHigh Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2
Sanche, S., Lin, Y. T., Xu, C., Romero-Severson, E., Hengartner, N., & Ke, R. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200282 · Cited by 1,619 · cited 1×
“Thus, models and intervention strategies should con- 280 sider that the overall R0 may be higher than 3 in certain 281 locations (5, 46).”
BackgroundCowling, B. J., Ali, S. T., Ng, T. W. Y., Tsang, T. K., Li, J. C. M., Fong, M. W., Liao, Q., Kwan, M. Y., Lee, S. L., Chiu, S. S., et al. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30090-6 · Cited by 1,258
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · cited 7×
“We assume that this herd immunity does not decay over the course of the study, since antibodies have been shown to persist for at least 5 mo (59).”
BackgroundInfluentialRobust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00902-8 · Cited by 392
Cited by
The Evolution and Biology of SARS-CoV-2 Variants
Telenti, A., Hodcroft, E. B., & Robertson, D. L. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041390 · Cited by 180
Infectious SARS-CoV-2 Is Emitted in Aerosol Particles
Hawks, S. A., Prussin, A. J., Kuchinsky, S. C., Pan, J., Marr, L. C., & Duggal, N. K. (2021) · mBio · doi:10.1128/mbio.02527-21 · Cited by 57
Metadata
- Authors
- Subramanian, R., He, Q., & Pascual, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-02-10
- Volume
- 118
- Issue
- 9
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3128463352
- Cited by
- 228
- References
- 16
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.